X
Xinyu Wei
Researcher at Celgene
Publications - 19
Citations - 5280
Xinyu Wei is an academic researcher from Celgene. The author has contributed to research in topics: Gemcitabine & Medicine. The author has an hindex of 7, co-authored 12 publications receiving 4306 citations.
Papers
More filters
Journal ArticleDOI
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff,Thomas J. Ervin,Francis P. Arena,E. Gabriela Chiorean,Jeffrey R. Infante,Malcolm J. Moore,Thomas E. Seay,Sergei Tjulandin,Wen Wee Ma,Mansoor N. Saleh,Marion Harris,Michele Reni,Scot Dowden,Daniel A. Laheru,Nathan Bahary,Ramesh K. Ramanathan,Josep Tabernero,Manuel Hidalgo,David Goldstein,Eric Van Cutsem,Xinyu Wei,Jose Iglesias,Markus F. Renschler +22 more
TL;DR: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.
Journal ArticleDOI
Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).
Daniel D. Von Hoff,Thomas J. Ervin,Francis P. Arena,E. Gabriela Chiorean,Jeffrey R. Infante,Malcolm J. Moore,Thomas E. Seay,Sergei Tjulandin,Wen Wee Ma,Mansoor N. Saleh,Marion Harris,Michele Reni,Ramesh K. Ramanathan,Josep Tabernero,Manuel Hidalgo,Eric Van Cutsem,David Goldstein,Xinyu Wei,Jose Iglesias,Markus F. Renschler +19 more
TL;DR: Nab-P provides tumor selective localization via transcytosis across the endothelium, potential tumor uptake via macropinocytosis, and improved pharmacokinetics vs cremophor-paclitaxel and in a phase I/II study in metastatic pancreatic cancer, nab-P + G showed promising activity.
Journal ArticleDOI
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel Plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo,Carlos Plaza,Monica Musteanu,Peter B. Illei,Carrie Baker Brachmann,Carla Heise,Daniel W. Pierce,Pedro P. López-Casas,Camino Menéndez,Josep Tabernero,Alfredo Romano,Xinyu Wei,Fernando López-Ríos,Daniel D. Von Hoff +13 more
TL;DR: SPARC levels were not associated with efficacy in patients with MPC, and this exploratory analysis does not support making treatment decisions regarding nab-paclitaxel plus gem citabine or gemcitabine alone in MPC based on SPARC expression.
Journal ArticleDOI
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.
Daniel D. Von Hoff,Thomas J. Ervin,Francis P. Arena,E. Gabriela Chiorean,Jeffrey R. Infante,Malcolm J. Moore,Thomas E. Seay,Sergei Tjulandin,Wen Wee Ma,Mansoor N. Saleh,Marion Harris,Michele Reni,Ramesh K. Ramanathan,Josep Tabernero,Manuel Hidalgo,Eric Van Cutsem,David Goldstein,Xinyu Wei,Jose Iglesias,Markus F. Renschler +19 more
TL;DR: A phase III study of nab-P + G vs G for metastatic PC and the primary endpoint was OS; secondary endpoints were PFS and ORR by independent review.
Journal ArticleDOI
O-0004sparc analysis in the phase iii mpact trial of nab-paclitaxel (nab-p) plus gemcitabine (gem) vs gem alone for patients with metastatic pancreatic cancer (pc)
Manuel Hidalgo,Carlos Plaza,P. Illei,Carrie Baker Brachmann,Carla Heise,Daniel W. Pierce,Alfredo Romano,Xinyu Wei,Fernando Lopez-Rios,D. D. Von Hoff +9 more
TL;DR: This study presents a novel and scalable approaches that allow for real-time decision-making about which drugs to give to patients and which are safe and effective for use in the clinic.